Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Johnson & johnson crawled date : 2022 - 02 - 18 save search
Global Brain Tumor Therapeutics Market (2021 to 2026) - Featuring Amgen, AstraZeneca and NextSource Among Others
Published: 2022-02-18 (Crawled : 22:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $140.3 1.13% -4.19% 0
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.54 0.6% 0.65% 8.5K
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
| Email alert
Add to watchlist
therapeutics train
Global Bladder Cancer Drug Market (2021 to 2026) - Unhygienic Workplace Exposure and Increase in Smoking Habits is Driving Growth
Published: 2022-02-18 (Crawled : 21:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
bladder cancer drug work cancer drug cancer growth bladder
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)
Published: 2022-02-18 (Crawled : 20:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
tremfya phase 2 disease active
Valued to be $6.8 Billion by 2026, Bipolar Disorder Therapeutics Slated for Robust Growth Worldwide
Published: 2022-02-18 (Crawled : 16:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 21K
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.14%
ALPMY | News | $9.49 -0.42% -1.11% 55K
|
Manufacturing
|
| O: -4.37%
H: 3.61%
C: 3.06%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -0.19%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -1.22%
H: 1.85%
C: 0.96%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -0.01%
H: 0.79%
C: 0.25%
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.46%
ALKS | $24.26 0.79% 0.78% 1.2M
|
Health Technology
|
| O: -0.71%
H: 3.54%
C: -0.36%
order therapeutics growth
Survivability Data Set Up New Prostate Cancer Indication for Bayer's Nubeqa
Published: 2022-02-18 (Crawled : 15:30) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
prostate cancer state cancer set
New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks
Published: 2022-02-18 (Crawled : 15:30) - prnewswire.com
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
tremfya phase 2 phase 2b response active pons ulcerative colitis
China Oncology Drugs Market to Cross $35.2 Billion by 2027 - Insights Into the Leading Therapies, Indications, Drugs, and Companies
Published: 2022-02-18 (Crawled : 15:30) - prnewswire.com
AZNCF | News | $140.3 1.13% -4.19% 0
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -2.99%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.46%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -1.02%
H: 0.43%
C: -0.84%
drug china therapy
BioSpace Movers & Shakers, Feb. 18
Published: 2022-02-18 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
VXRT | News | $0.7454 -2.24% -2.74% 1.6M
|
Health Technology
|
| O: 0.0%
H: 2.95%
C: 0.21%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
BMRN | $92.06 2.87% 2.79% 1.3M
|
Health Technology
|
| O: -1.89%
H: 1.47%
C: -4.21%
ALEC | $5.34 3.29% 3.0% 550K
|
Health Technology
|
| O: -0.37%
H: 3.37%
C: 2.06%
space spac
BioArctic continues to build its commercial organization
Published: 2022-02-18 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
commercialization
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
Your saved searches
Save your searches and get alerts when important news are released.